← All approvals · Weight loss & diabetes · 2026
Foundayo (orforglipron)
The FDA approved Foundayo (orforglipron) on April 1, 2026 to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity.
- Brand name
- Foundayo
- Generic name
- orforglipron
- FDA approval date
- April 1, 2026
- Approved use (FDA wording)
- To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity
- Company
- Eli Lilly And Co
- Application
- NDA220934
- Dosage form / route
- TABLET · ORAL
- Boxed warning on label
- Yes (see the FDA label)
- Category on this site
- Weight loss & diabetes
Indications and usage, from the FDA label
FOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended. ( 1 ) Limi…